MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-12.49M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -139.00% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.06 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.06 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-3.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.56 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.97 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 4.97M |
| Free Float | 3.85M |
| Market Capitalization | $70.57M |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | 0.35 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 2.87% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |